Science Links Japan | Matrix Metalloproteinase-9 Is a Marker of Heart Failure After Acute Myocardial Infarction

Matrix Metalloproteinase-9 Is a Marker of Heart Failure After Acute Myocardial Infarction

Accession number;06A0128130

Title;Matrix Metalloproteinase-9 Is a Marker of Heart Failure After Acute Myocardial Infarction

Author; WAGNER DANIEL R. (From The Div. Of Cardiology, Centre Hospitalier, Luxembourg) WAGNER DANIEL R. (Lab. Of Cardiovascular Res., Centre De Rech. Public Sante, Luxembourg) DELAGARDELLE CHARLES (From The Div. Of Cardiology, Centre Hospitalier, Luxembourg) ERNENS ISABELLE (Lab. Of Cardiovascular Res., Centre De Rech. Public Sante, Luxembourg) ROUY DIDIER (Lab. Of Cardiovascular Res., Centre De Rech. Public Sante, Luxembourg) VAILLANT MICHEL (Center For Health Studies, Epidemiology And Technol. Transfer, Centre De Rech. Public Sante, Luxembourg) BEISSEL JEAN (From The Div. Of Cardiology, Centre Hospitalier, Luxembourg)

Journal Title;J Card Fail

Journal Code:W1342A

ISSN:1071-9164

VOL.12;NO.1;PAGE.66-72(2006)

Figure&Table&Reference;FIG.4, TBL.2, REF.27

Pub. Country;United States

Language;English

Abstract;Matrix metalloproteinases (MMPs) have been associated with the development of left ventricular remodeling after myocardial infarction (MI). We sought to determine whether peripheral levels of MMPs can be used as a risk marker for the development of congestive heart failure (CHF) after acute MI. Plasma levels of MMP-2, MMP-9, C-reactive protein (hs-CRP), tumor necrosis factor-.ALPHA. (TNF-.ALPHA.), and pro-brain natriuretic peptide (pro-BNP) were measured in 109 consecutive patients with acute MI treated with primary mechanical reperfusion. Echocardiographic assessment of left ventricular wall motion index was performed during admission. Patients were followed for the development of CHF. Left ventricular function and volumes were determined after 2 years with radionuclide ventriculography. During 2-year follow-up, 15 patients developed congestive heart failure (CHF). Using multivariate analysis, MMP-9 levels were the only circulating factor predictive of late onset CHF. Patients who had high MMP-9 levels had a significant risk of late onset CHF (OR of 6.5, P .LEQ. .006) and left ventricular remodeling (.DELTA.EF = -9%, P = .03, and .DELTA.end-diastolic volume = +13 mL, P = .03). MMP-2, TNF-.ALPHA., hs-CRP, creatine kinase, and pro-BNP were not predictive of late onset CHF. MMP-9 levels may hold prognostic significance in MI patients. Copyright 2006 Elsevier B.V., Amsterdam.All rights reserved.

Related Articles;